title: Sustained-release IS-5-MN in the treatment of coronary heart disease.
abstract: In a double-blind, randomized cross-over study the antianginal efficacy and tolerability of Elantan Long (50 mg sustained-release IS-5-MN) were compared with a 80-mg sustained-release (s.r.) IS-5-MN formulation. 28 patients were enrolled in the study, which consisted of a 3-day washout period on placebo, an active treatment of 14 days (cross-over after 7 days) and a final 3-day withdrawal period on placebo. Ergometric exercise tests with simultaneous ECG monitoring were carried out 2 and 10 h post administration (p.a.) on the last days of each period. Under 50 mg s.r. IS-5-MN the mean ST- segment depression under comparable load was reduced by 67% 2 h p.a. and by 70% 10 h p.a. The reduction under the 80 mg IS-5-MN form was about 76% 2 h p.a. and 78% 10 h p.a. Maximum workload, working capacity, duration of exercise, time to angina pectoris and time to ST-segment depression greater than 0.1 mV were markedly increased under therapy with each dosage. Comparisons between the medications revealed significant differences only in time to ST-segment depression greater than 0.1 mV and in ST-segment depression under maximum workload at 10 h p.a. which were increased more by the higher dosage. The incidence of anginal attacks decreased by almost 80% in the patients under both treatments. Ten patients under each dosage were completely freed from attacks. Adverse drug reactions occurred in 14 patients, 10 times under 80 mg s.r. IS-5-MN, 5 times under Elantan Long and twice under placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Kurklinik der LVA, Bad Münster am Stein, FRG.
authors.forename: M
authors.initials: M
authors.lastname: Keck
mesh_terms: D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004562:Electrocardiography; D005080:Exercise Test; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008991:Monitoring, Physiologic
chemical_list: D003692:Delayed-Action Preparations; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate